Eplerenone relieves spironolactone-induced painful gynaecomastia in a patient with primary aldosteronism [17]

Nephrology Dialysis Transplantation

Volumn 22, Issue 1, 2007, Pages 293-

  Karagiannis, Asterios ^a   Tziomalos, Konstantinos ^a   Kakafika, Anna ^a   Florentin, Matilda ^a   Athyros, Vassilios Gabriel ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; EPLERENONE; POTASSIUM; SODIUM CHLORIDE; SPIRONOLACTONE;

ADULT; ALDOSTERONE BLOOD LEVEL; BLOOD PRESSURE REGULATION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GYNECOMASTIA; HUMAN; HYPERTENSION; HYPOKALEMIA; LETTER; MALE; MASTALGIA; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ALDOSTERONE; CLINICAL TRIALS; GYNECOMASTIA; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; MALE; MIDDLE AGED; RECEPTORS, ALDOSTERONE; RENIN; SEX FACTORS; SPIRONOLACTONE;

EID: 33846020025     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl500     Document Type: Letter

References (4)

1. Menard J. The 45-year story of the development of an antialdosterone more specific than spironolactone. Mol Cell Endocrinol 2004; 217: 45-52
2. Garthwaite SM, McMahon EG. The evolution of aldosterone antagonists. Mol Cell Endocrinol 2004; 217: 27-31
3. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 1999; 341: 709-717
4. Pitt B, Williams G, Remme W et al. The EPHESUS trial: Eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone post-AMI heart failure efficacy and survival study. Cardiovasc Drugs Ther 2001; 15: 79-87